Insys Therapeutics (INSY) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Insys Therapeutics Reports Second Quarter 2016 Results
August 3, 2016 6:50 AM EDTPHOENIX, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended June 30, 2016.
Highlights of and subsequent to the second quarter of 2016 include:
Total net revenue was $67.1 million, compared to $77.6 million for the second quarter of 2015;Net income totaled $4.4 million, or $0.06 per basic and $0.06 per diluted share, compared to net income of $7.3 million, or $0.10 per basic and $0.10 per diluted share, for the second quarter of 2015;Cash, cash equivalents and investments were $193.7 million as of June 30, 2016;... More